Neurology
FDA/CDC
What to know about newly approved Alzheimer’s drug
The drug has shown moderate positive effects in clinical trials in slowing early...
FDA/CDC
FDA approves second antiamyloid for Alzheimer’s disease
Like its controversial cousin aducanumab, lecanemab was approved under the FDA’s accelerated approval pathway.
Latest News
Compulsively checking social media linked with altered brain patterns in teens
It’s unclear what’s driving the differences in adolescent brains, an expert warns.
FDA/CDC
FDA considers regulating CBD products
The products can have drug-like effects on the body and contain CBD (cannabidiol) and THC (tetrahydrocannabinol).
From the Journals
Strong link between muscle strength, mobility, and brain health
“The implication is that muscular strength and mobility influence brain health.”
News from the FDA/CDC
Alzheimer’s Association to CMS: Ditch restraints on amyloid drugs
The CMS coverage restrictions for anti-amyloid drugs were finalized in April on the...
From the Journals
Cluster headache tied to high risk of mental and neurologic disorders
Although cluster headaches are often more prevalent in men, researchers found that multimorbidity rates were significantly higher in women.
Conference Coverage
Antipsychotic shows benefit for Alzheimer’s agitation
Currently, there’s no Food and Drug Administration–approved treatment for agitation in AD.
From the Journals
Noninvasive laser therapy tied to improved short-term memory
Patients with attention-related conditions ‘could benefit from this type of treatment,’ expert says.
Conference Coverage
Seizures in dementia hasten decline and death
Dementia patients who also had active seizures had shorter life expectancy and earlier decline than dementia patients who didn’t have active...
Conference Coverage
SSRI tied to improved cognition in comorbid depression, dementia
Evidence suggests the drug’s receptor targets “have the potential to modulate neurotransmitter systems that are essential for regulation of...